University Cancer & Blood Center is proud to be the first cancer center in Georgia to offer Pluvicto® as part of our innovative Theranostics program.
Pluvicto® is the first FDA-approved targeted radioligand therapy (RLT) that combines a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle). Pluvicto® is an eligible treatment option for adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has already spread to other parts of the body. Eligible patients will have already been treated with other anticancer treatments, like androgen receptor pathway inhibition and taxane-based chemotherapy.
By first injecting the FDA-approved imaging agent, Locametz (Gallium 68), doctors are able to radiolabel the PSMA-positive cancer cells through PET/CAT scans. After radiolabeling and identifying the PSMA biomarkers throughout a patient’s body, they will be eligible for targeted treatment with Pluvicto®.
Pluvicto® (Lutetium 177) is able to specifically target these marked PSMA-positive areas and attach itself to the target cells throughout the body, destroying the specific cancerous cells through emissions from the radioisotope without damaging the healthy tissue in the area.
If you or your doctor would like to better understand if Pluvicto® is right for you or if you are eligible for this innovative cancer therapy treatment, please reach out to University Cancer & Blood Center today.
Contact Us For More Information
HOW IT WORKS:
PLUVICTO TARGETS PSMA-POSITIVE CELLS, INCLUDING PROSTATE CANCER CELLS
PLUVICTO is comprised of 2 key components: lutetium-177, a cytotoxic radionuclide, and PSMA-617, a PSMA-targeting ligand.
PLUVICTO binds to PSMA, a transmembrane protein expressed on prostate cancer cells. After binding to PSMA, PLUVICTO undergoes endocytosis and is internalized into the cell.
Lutetium-177, the cytotoxic radionuclide of PLUVICTO, emits DNA-breaking radiation within the cell. The short path length of the radiation emitted by PLUVICTO, approximately 2 millimeters maximum, causes single- and double-stranded DNA breaks in targeted cells as well as surrounding cells, which can lead to cell death.
